Skip to content
value.today

BioRestorative Therapies, Inc.

BRTX
$6 Mmarket cap on Aug 1, 2026-25.0% since Jan 2024
Compare
World rank
#26,621
Revenue
$0 M
For year ending December-2025
Net income
$-14 M
-3955.6% margin
SEC filing
Employees
14
As of December 31, 2025
SEC filing

BioRestorative Therapies, Inc. in brief

BioRestorative Therapies, Inc. is a listed company in the Healthcare sector, based in Melville, New York, USA. Its market value was $6 M on 1 August 2026, which makes it the 26,621st largest listed company in the world and the 4,372nd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $14 M. It employs about 14 people. Its largest product and service lines by sales in 2025 were Royalty (17%). Its shares trade under the symbol BRTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About BioRestorative Therapies, Inc.

We were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from “Stem Cell Assurance, Inc.” to “BioRestorative Therapies, Inc.” Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we reincorporated in Nevada.

We are currently pursuing our Disc/Spine Program with our initial investigational therapeutic product being called BRTX-100. In March 2022, a United States patent issued in our Disc/Spine Program. We are conducting a Phase 2 clinical trial investigating the use of BRTX-100 in the treatment of chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration, or the FDA, Investigational New Drug, or IND, clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

From the company's annual report filed with the US SEC: read the report

BioRestorative Therapies, Inc. timeline

3 events, 2010–2024
  1. 2010
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2011
  4. ✎
    Renamed BioRestorative Therapies, Inc.
    Formerly Stem Cell Assurance, Inc..
  5. 2024
  6. 💰
    Record revenue of $0 million
    FY2024, the highest of the 8 years on record.

Events of BioRestorative Therapies, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$4 M$8 M$11 M$15 M2023202420252026

World rank over time

▲ up 10,053 places since 2022
2022-01-07: #33501#33,50120222022-12-25: #31186#31,18620222023-07-30: #31326#31,32620232024-01-05: #31650#31,65020242026-03-08: #13544#13,54420262026-08-01: #23448#23,4482026

Rank in USA: #5,536 (Jan 2022) · #5,529 (Dec 2022) · #5,392 (Jul 2023) · #4,557 (Jan 2024) · #2,486 (Mar 2026) · #4,099 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
16.7×
Price / book
16.7×
Free cash flow yield
-181.8%
Net margin (TTM)
-3069.4%
Operating margin
-4347.2%
Return on equity
-3069.4%
Liabilities / assets
91.2%
Net debt
$-21M
Revenue growth
-10.0%
R&D / revenue
2802.8%
Revenue per employee
$26 K
Profit per employee
$-1.0 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-13M$0MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-15M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-11M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-44M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-13M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-10M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-9M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-14M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M-10.0%$-16M$-14M-3955.6%
Dec 2024$0M+166.7%$-12M$-9M-2245.0%
Dec 2023$0M+25.0%$-15M$-10M-6946.7%
Dec 2022$0M+140.0%$-19M$-13M-11016.7%
Dec 2021$0M-37.5%$-26M$-44M-88600.0%
Dec 2020$0M-38.5%$-3M$-11M-14087.5%
Dec 2019$0M+18.2%$-8M$-15M-11269.2%
Dec 2018$0M—$-8M$-13M-11381.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M$0M$-11M$-1.58—
Dec 2024$-8M$0M$-8M$-1.16—
Dec 2023$-6M$0M$-7M$-2.47—
Dec 2022$-6M$0M$-6M$-3.65—
Dec 2021$-3M$0M$-3M$-37.30—
Dec 2020$-2M——$-28.56—
Dec 2019$-7M$0M$-7M$-0.66—
Dec 2018$-5M$0M$-5M$-1.64—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$0M
Net income, trailing 12 months
$-11M
RevenueNet income
Three months to Jun 2024: revenue $0M, net income $-4M$0MJun ’24Three months to Sep 2024: revenue $0M, net income $-1M$0MSep ’24Three months to Dec 2024 (from the annual report): revenue $0M, net income $-2M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-5M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-3M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-3M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-3M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-2M$0MMar ’26

Latest quarter to Mar 2026: revenue $0M (0.0% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2026.

SEC filings

Official filings of BioRestorative Therapies, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-16 M
Net income
$-14 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$4 M
Total liabilities
$4 M
Total equity
$0 M

As of December-2025

Top 14 institutional investors in BioRestorative Therapies, Inc.#

As of Sep 30, 2026
14 institutions held 87,987 shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 14 largest institutional investors in BioRestorative Therapies, Inc.
#InstitutionShares heldChange (shares)ValueFiled
1Citadel Advisors LLC30,951New$0 MNov 16, 2026
2Jane Street Group, LLC27,156New$0 MNov 12, 2026
3HRT Financial LP14,194New$0 MNov 13, 2026
4Vanguard Fiduciary Trust Co9,065New$0 MNov 13, 2026
5UBS Group AG3,422New$0 MNov 10, 2026
6Vanguard Capital Management LLC2,134New$0 MNov 13, 2026
7Tower Research Capital LLC (TRC)864New$0 MNov 16, 2026
8Osaic Holdings, Inc.100New$0 MNov 12, 2026
9SBI Securities Co., Ltd.91New$0 MOct 22, 2026
10Rossby Financial, LCC5New$0 MNov 5, 2026
11TD Waterhouse Canada Inc.2New$0 MOct 16, 2026
12Citigroup Inc1New$0 MNov 4, 2026
13UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC1New$0 MNov 16, 2026
14Parallel Advisors, LLC1New$0 MNov 3, 2026

Mutual funds holding BioRestorative Therapies, Inc.#

4 funds hold shares worth $0 M. Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding BioRestorative Therapies, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC193,321$0 M—<0.01%+555%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC13,405$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC8,558$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC3,862$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at BioRestorative Therapies, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
15
since
$368 K-$2 K$0Nov 2023: bought $0 (0 trades), sold $525 (1 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $470 (1 trades)DecFeb 2024: bought $368 K (4 trades), sold $0 (0 trades)FebApr 2024: bought $10 K (3 trades), sold $0 (0 trades)AprOct 2024: bought $0 (0 trades), sold $2 K (1 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
BioRestorative Therapies, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Lance AlstodtPresident, CEO, COB, Director, 10% ownerGrant or award+15,625$1.600$25 K187,497Form 4
filed Francisco SilvaVP of Research and Development, DirectorGrant or award+11,719$1.600$19 K171,384Form 4
filed Dale Broadrick10% ownerSell-1,112$1.580$2 K445,933Form 4
filed Francisco SilvaVP of Research and Development, DirectorBuy+6,600$1.250$8 K155,759Form 4
filed Francisco SilvaVP of Research and Development, DirectorBuy+476$1.130$538147,927Form 4
filed Francisco SilvaVP of Research and Development, DirectorBuy+1,232$1.170$1 K149,159Form 4
filed Francisco SilvaVP of Research and Development, DirectorShares withheld for tax-17,193$1.390$24 K147,451Form 4
filed Lance AlstodtPresident, CEO, COB, DirectorShares withheld for tax-17,633$1.390$25 K171,872Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: BioRestorative Therapies, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
36,404
0.4% of shares · 1 days to cover
Buybacks, Q1 2026
$0M
Q1 2026
Shares sold short, last 24 reportsAll stocks →

Bankruptcy filing: (8-K); (8-K); (8-K); (8-K); (8-K)

BioRestorative Therapies, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2026Q1 2026$0M
Q1 2014Q1 2014$0M
Q4 2013Q4 2013$0M
Q3 2013Q3 2013$0M
Q2 2013Q2 2013$0M
Q1 2013Q1 2013$0M
Q4 2012Q4 2012$0M
Q3 2012Q3 2012$0M
Q2 2012Q2 2013$0M
Q1 2012Q1 2013$0M
Q4 2011Q4 2011$0M
Q3 2011Q3 2011$0M
Q4 2010Q4 2011$0M

Trading halts

  • 2026-09-04 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 4,516 shares at $1.58
  • : 963 shares at $1.43
  • : 48 shares at $1.49
  • : 479 shares at $1.62
  • : 97 shares at $1.53

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

BioRestorative Therapies, Inc. scorecard#

Passes 0 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.58 vs -1.16Diluted EPS -1.58 in fiscal 2025 against -1.16 the year before (report's currency).
    • ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$11 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-320.4%-320.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.84 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-70.08Z-score -70.08 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year15.8%Diluted shares up 15.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

BioRestorative Therapies, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

BioRestorative Therapies, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.40.40.10.10.00.10.10.10.10.0
Cost of revenue0.00.0———————0.0
Gross profit0.30.40.1—————0.10.0
Research and development106.7r4.03.50.70.91.71.52.22.9
General and administrative5.95.2r111626r1.84.64.03.93.2r
Operating expenses16121519262.88.67.88.57.8r
Operating income−16−12−15−19−26−2.8−8.4−7.6−8.4−7.8r
Interest and finance income0.30.60.60.1——————
Interest expense and finance costs————————0.20.0
Net interest income0.30.60.60.0−1.8—————
Other non-operating income (expense)1.42.64.8r5.8r−18−8.5−6.2−4.9−1.1−0.9r
Income before tax−14−9.0——————−9.4−8.6
Net income attributable to shareholders−14−9.0−10r−13r−44−11−15−13−9.4−8.6
Earnings per share, basic-1.58-1.16-2.47r-3.65r-37.30-28.56r-0.66-1.64-1.74-2.10
Earnings per share, diluted-1.58-1.16-2.47r-3.65r-37.30-28.56r-0.66-1.64-1.74-2.10
Shares, weighted average (basic)9.07.84.23.61.2—————
Shares, weighted average (diluted)9.07.84.23.61.20.4r227.65.44.1
Balance sheet
Cash and cash equivalents1.50.50.91.7r213.10.00.10.50.0
Short-term investments1.4101013r——————
Receivables0.00.20.00.00.00.00.00.00.00.0
Other current assets0.20.20.30.40.4——0.00.00.0r
Current assets3.1111115213.20.10.20.50.1r
Property, plant and equipment0.40.40.40.30.00.00.10.20.30.5
Right-of-use (leased) assets——0.20.20.40.50.6———
Other intangible assets0.50.60.70.80.60.70.70.80.91.0
Total assets4.1121316224.31.51.21.81.6
Accounts payable1.30.50.20.20.10.12.01.92.52.3
Current liabilities3.73.72.6r6.0r0.41.0149.38.45.8
Lease liabilities (non-current)———0.20.30.40.5———
Total liabilities—3.72.6r6.1r0.95.7149.88.66.6
Retained earnings−170−156−147r−136r−134−90−79−64−51−42
Shareholders' equity0.48.510r10r11r−1.3−13−8.6−6.8−5.0
Total liabilities and equity4.1121316224.31.51.21.81.6
Shares outstanding8.96.94.73.73.50.7r78126.14.7
Cash-flow statement
Depreciation and amortization0.20.20.20.10.10.10.20.20.30.3
Share-based compensation3.32.87.813230.71.72.43.62.5
Cash from operating activities−11−8.2−6.4−5.9r−3.3−2.0−6.9−5.1−3.9−5.0
Capital expenditure−0.1−0.1−0.2−0.3−0.0—−0.0−0.0−0.0−0.2
Intangible assets bought———−0.2——————
Cash from investing activities8.90.53.3−13r−0.0—−0.0−0.0−0.0−0.2
Debt repaid————————−0.1−0.3
Shares issued3.1—0.5r———————
Shares bought back0—————————
Cash from financing activities2.97.42.3r—215.0r6.84.84.35.1
Change in cash1.0−0.3−0.8r−19r183.1−0.1−0.30.4—
Report10-K10-K10-K10-K/A10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What BioRestorative Therapies, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$0 M83%
  • Royalty$0 M17%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at BioRestorative Therapies, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 1 · Auditor changed 3 · Directors and officers 9 · Material agreement 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 5

BioRestorative Therapies, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Auditor changed8-K/A
Auditor changedDirectors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Delisting notice8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of BioRestorative Therapies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$1 MPrivate placement after listingUnder $2 million16equity, optionsSEC
Jan 2014$14 MPrivate placement after listing$10 to $50 million81equity, optionsSEC
Apr 2012$2 MNo. 2Under $2 million6equity, debt, optionsSEC
Nov 2010$1 MNo. 1Under $2 million15equity, debtSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at BioRestorative Therapies, Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $71 K a year.

Certified, FY2026
2
#1,570 among companies on value.today
Worker positions
2
Median wage offered
$71 K
a year, full-time
Applications filed
2
BioRestorative Therapies, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior QC AnalystBiological Technicians2$71 K

Where: Melville, NY 2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Biorestorative Therapies Inc.

How BioRestorative Therapies, Inc. compares in Healthcare

  • Market cap$6 M · higher than 5% of 2,013
  • Revenue$0 M · higher than 9% of 1,795
  • Revenue growth-10.0% · higher than 21% of 1,003
  • Price / sales16.7× · lower than 15% of 1,071
  • Price / book16.7× · lower than 8% of 1,245
  • FCF yield-181.8% · higher than 1% of 835
CompanyMarket capP/ENet marginRev. growth
BioRestorative Therapies, Inc.🇺🇸$6 M——-10.0%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BioRestorative Therapies, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BioRestorative Therapies, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BioRestorative Therapies, Inc.? Suggest a correction